Evaluating Construct and Criterion validity of NeuroScreen in Assessing Neurocognition among Hospitalized Ugandan First-episode Psychosis Patients

Simple item page
dc.contributor.authorAsiedu, Nana
dc.contributor.authorMwesiga, Emmanuel Kiiza
dc.contributor.authorAkena, Dickens
dc.contributor.authorGumikiriza-Onoria, Joy Louise
dc.contributor.authorNanteza, Angel
dc.contributor.authorNakku, Juliet
dc.contributor.authorNakasujja, Noeline
dc.contributor.authorSsembajjwe, Wilber
dc.contributor.authorFerraris, Christopher M.
dc.contributor.authorSantoro, Anthony F.
dc.contributor.authorRobbins, Reuben N.
dc.date.accessioned2023-03-06T14:56:08Z
dc.date.available2023-03-06T14:56:08Z
dc.date.issued2023
dc.description.abstractNeurocognitive impairment (NCI) is commonly exhibited among patients experiencing their first episode of psychosis. However, there are few resources in many low-income countries, such as Uganda, that allow for the administration of extensive neurocognitive test batteries for the detection of NCI. NeuroScreen is a brief tablet-based neurocognitive assessment battery that can be administered by all levels of healthcare staff. We examined the validity of NeuroScreen to assess neurocognition and detect NCI in first-episode psychosis (FEP) patients in Uganda. We enrolled 112 participants FEP patients and matched controls at Butabika Mental Referral Hospital. Each participant completed NeuroScreen and a traditionally administered neurocognitive battery: the MATRIC Consensus Cognitive Battery (MCCB). We examined correlations between participant performance on NeuroScreen and the MCCB. A ROC curve determined sensitivity and specificity of NeuroScreen to detect NCI as determined by MCCB criterion. There was a large, statistically significant correlation between overall performance on NeuroScreen and the MCCB [r(112) = 0.64, p < .001]. Small to large correlations were found between tests in the MCCB and NeuroScreen batteries. The ROC curve of NeuroScreen performance to detect MCCB-defined NCI had an area under curve of 0.80 and optimal sensitivity and specificity of 83 % and 60 %, respectively. There was a moderate positive correlation between overall performance on both batteries. NeuroScreen shows promise as a valid assessment battery to assess neurocognition and detect NCI in FEP patients in Uganda. Further studies of NeuroScreen in healthy individuals and in a range of mental disorders are recommended.en_US
dc.identifier.citationAsiedu, N., Mwesiga, E. K., Akena, D., Morrison, C., Gumikiriza-Onoria, J. L., Nanteza, A., ... & Robbins, R. N. (2023). Evaluating construct and criterion validity of NeuroScreen in assessing neurocognition among hospitalized Ugandan first-episode psychosis patients. Schizophrenia Research: Cognition, 32, 100276.https://doi.org/10.1016/j.scog.2022.100276en_US
dc.identifier.issn2215-0013
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/8081
dc.language.isoenen_US
dc.publisherSchizophrenia Research: Cognitionen_US
dc.subjectNeurocognitive impairmenten_US
dc.subjectFirst episode psychosisen_US
dc.subjectNeuroScreenen_US
dc.subjectMATRIC consensus cognitive batteryen_US
dc.subjectNeuropsychological assessmenten_US
dc.subjectLow-income countryen_US
dc.titleEvaluating Construct and Criterion validity of NeuroScreen in Assessing Neurocognition among Hospitalized Ugandan First-episode Psychosis Patientsen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Evaluating construct and criterion validity of NeuroScreen in assessing neurocognition among hospitalized Ugandan first-episode psychosis patients.pdf
Size:
1.81 MB
Format:
Adobe Portable Document Format
Description:
Evaluating construct and criterion validity of NeuroScreen in assessing neurocognition among hospitalized Ugandan first-episode psychosis patients
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences